Reckitt Benckiser Group (OTCMKTS:RBGLY) Stock Rating Upgraded by Citigroup

Reckitt Benckiser Group (OTCMKTS:RBGLY) was upgraded by Citigroup to a “strong-buy” rating in a research report issued on Tuesday, Zacks.com reports.

Several other equities research analysts have also weighed in on RBGLY. UBS Group raised Reckitt Benckiser Group to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded shares of Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 29th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Reckitt Benckiser Group currently has an average rating of “Hold”.

Reckitt Benckiser Group Price Performance

Shares of OTCMKTS RBGLY opened at $12.23 on Tuesday. The stock has a fifty day simple moving average of $11.54 and a two-hundred day simple moving average of $11.29. Reckitt Benckiser Group has a 1-year low of $10.24 and a 1-year high of $15.03.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.